Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$44.64 USD

44.64
6,945,846

0.00 (0.00%)

Updated Apr 30, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.74, signifying a -0.47% move from its prior day's close.

Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study

by Zacks Equity Research

Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.

Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.

Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

by Zacks Equity Research

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

by Zacks Equity Research

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.

Bristol Myers Squibb (BMY) Stock Moves -0.29%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $52.34, moving -0.29% from the previous trading session.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.

Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II

by Zacks Equity Research

Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.

Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $50.89, indicating a +0.28% shift from the previous trading day.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.

New Strong Sell Stocks for February 26th

by Zacks Equity Research

BXMT, BMY and CWEN have been added to the Zacks Rank #5 (Strong Sell) List on February 26, 2023.

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

by Zacks Equity Research

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

by Zacks Equity Research

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.